Quick Answer
Relay Therapeutics, Inc. reported Net Income Loss of -$276.48 million for the year ending 2025.
- Relay Therapeutics, Inc. showed an increase of +18.1% in Net Income Loss from 2024 to 2025.
- This data is from Relay Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 7 years of available data (2019 to 2025), Relay Therapeutics, Inc.'s Net Income Loss has declined by 267.1%.
- Historical annual values: Fiscal year 2025: -$276.48 million | Fiscal year 2024: -$337.71 million | Fiscal year 2023: -$341.97 million | Fiscal year 2022: -$290.51 million | Fiscal year 2021: -$363.87 million | Fiscal year 2020: -$52.41 million | Fiscal year 2019: -$75.31 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: